晚期卵巢癌初次肿瘤细胞减灭术中行胸腔内手术:迈向新高度——纪念斯隆-凯特琳癌症中心研究
该研究回顾了2006年1月1日至2021年9月30日在本院接受初次肿瘤细胞减灭术的IIIB-IV期卵巢癌患者,其中178例接受胸腔内肿瘤细胞减灭术;腹部和胸腔完全肉眼切除(CGR)率达74%,至少1例≥3级并发症发生率为17%,中位无进展生存期(PFS)为33.6个月,中位总生存期(OS)为81.3个月,达到CGR者PFS和OS均显著改善。
要点
- 178例晚期卵巢癌患者接受胸腔内肿瘤细胞减灭术,腹部和胸腔CGR率达74%。
- 17%患者发生至少1例≥3级并发症,其中8例可能与胸腔内手术相关,术后30天内无死亡。
- 达到CGR者中位PFS 51.8个月 vs 有残留病灶者16.7个月(HR 2.17,P<.001),中位OS 97.6个月 vs 65.9个月(HR 2.05,P=.003)。
核心结论
- 对于晚期卵巢癌,初次肿瘤细胞减灭术中行胸腔内肿瘤细胞减灭术安全且可行。
- 经过适当选择的胸腔内病变患者可达到完全肉眼切除,并可能显著改善PFS和OS。
研究设计与样本
- 本研究为数据库回顾性分析,纳入2006年1月1日至2021年9月30日在本院接受初次肿瘤细胞减灭术的IIIB-IV期卵巢癌(包括输卵管癌和原发性腹膜癌)患者。
- 纳入标准为接受胸腔内肿瘤细胞减灭术作为初始治疗组成部分的患者;排除接受新辅助化疗或非肿瘤细胞减灭目的手术的患者。
- 共纳入178例患者。
主要发现
- 腹部和胸腔完全肉眼切除(CGR)131例(74%),最佳肿瘤细胞减灭45例(25%),次佳肿瘤细胞减灭2例(1%)。
- 31例(17%)发生至少1例≥3级并发症,其中8例可能与胸腔内肿瘤细胞减灭术相关;术后30天内无死亡。
- 存活者中位随访时间53.4个月;全部患者中位PFS为33.6个月(95% CI: 24.7-61.9),3年PFS率为48.9%(95% CI: 41.2%-56.2%),中位OS为81.3个月(95% CI: 68.9-103)。
- 按残留病灶状态分层,达到CGR者中位PFS为51.8个月 vs 有残留病灶者16.7个月(HR: 2.17;P < .001);达到CGR者中位OS为97.6个月 vs 有残留病灶者65.9个月(HR: 2.05;P = .003)。
临床怎么用
- 原文结论认为,对晚期卵巢癌患者,初次肿瘤细胞减灭术中行胸腔内肿瘤细胞减灭术安全且可行。
- 原文结论认为,经过适当选择的胸腔内病变患者可达到CGR,并可能显著改善PFS和OS。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We investigated the feasibility, safety, and survival outcomes of intrathoracic cytoreduction during primary debulking surgery (PDS) for advanced ovarian cancer. METHODS: We conducted a database review of patients with stage IIIB-IV ovarian (including fallopian tube and primary peritoneal) carcinoma who underwent PDS at our institution from 01/01/2006-9/30/2021. Patients who underwent intrathoracic cytoreduction as part of primary treatment were included. Patients who received neoadjuvant chemotherapy or surgery for reasons other than cytoreduction were excluded. RESULTS: Among 178 patients identified for inclusion, complete gross resection (CGR) in the abdomen and thorax was achieved in 131 (74%); 45 (25%) had optimal cytoreduction, and 2 (1%) had suboptimal cytoreduction. Thirty-one patients (17%) had at least one grade ≥ 3 complication; 8 were possibly related to intrathoracic cytoreduction. There were no deaths within 30 days following surgery. Median length of follow-up among survivors was 53.4 months. Among all patients, the median PFS was 33.6 months (95% CI: 24.7-61.9) and the 3-year PFS rate was 48.9% (95% CI: 41.2%-56.2%). Median OS was 81.3 months (95% CI: 68.9-103). When stratified by residual disease status, median PFS was 51.8 months when CGR was achieved versus 16.7 months with residual disease (HR: 2.17; P < .001) and median OS was 97.6 months when CGR was achieved versus 65.9 months with residual disease (HR: 2.05; P = .003). CONCLUSIONS: Intrathoracic cytoreduction during PDS for advanced ovarian cancer is both safe and feasible. CGR can be achieved in patients with intrathoracic disease if properly selected, and could significantly improve both PFS and OS.
引用
- Kahn RM, McMinn E, Yeoshoua E, et al. Intrathoracic surgery as part of primary cytoreduction for advanced ovarian cancer: Going to the next level - A Memorial Sloan Kettering Cancer Center study. Gynecol Oncol. 2023. PMID: 36621269. doi:10.1016/j.ygyno.2022.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。